Loxo spikes on response data in NTRK-positive cancer

Loxo Oncology Inc. gained $21.14 (43%) to $70.12 on Monday after it said pooled data from three trials of larotrectinib (LOXO-101) showed a confirmed objective response rate (ORR) of 76%, including a complete response (CR) rate of 12%, in patients with neurotrophic tyrosine kinase (NTRK) fusions. The company plans to submit an NDA to FDA by early next year seeking the candidate's approval in NTRK fusion-positive cancers, regardless of tumor type.

Loxo ended the day with a market cap of more than $1.8 billion...